• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Authors » David Ho

David Ho

Articles

ARTICLES

Singapore's A*STAR draws pharma, academia to boost manufacturing innovations

Oct. 31, 2018
By David Ho
HONG KONG – Singapore's Agency for Science, Technology and Research (A*STAR) has initiated the Pharma Innovation Programme Singapore (PIPS) aimed at bringing together the city-state's public sector research capabilities and major global players in the pharma industry to transform the manufacturing operations and technologies of the industry for greater efficiencies.
Read More

Singapore's A*STAR draws pharma, academia to boost manufacturing innovations

Oct. 30, 2018
By David Ho
HONG KONG – Singapore's Agency for Science, Technology and Research (A*STAR) has initiated the Pharma Innovation Programme Singapore (PIPS) aimed at bringing together the city-state's public sector research capabilities and major global players in the pharma industry to transform the manufacturing operations and technologies of the industry for greater efficiencies.
Read More

Maz offers ostrich antibody IP in A*STAR collaboration targeting dengue viruses

Oct. 24, 2018
By David Ho
HONG KONG – Biotech company Maz World Ltd. is working with the Institute of Molecular and Cell Biology of Singapore's Agency for Science, Technology and Research (IMCB A*STAR) to use its ostrich antibody technology to neutralize the four serotypes of dengue viruses.
Read More

Maz offers ostrich antibody IP in A*STAR collaboration targeting dengue viruses

Oct. 23, 2018
By David Ho
HONG KONG – Biotech company Maz World Ltd. is working with the Institute of Molecular and Cell Biology of Singapore's Agency for Science, Technology and Research (IMCB A*STAR) to use its ostrich antibody technology to neutralize the four serotypes of dengue viruses.
Read More

Standards being introduced to 1,000+ med devices as price caps cause disputes in India

Oct. 11, 2018
By David Ho

Xact wins CE mark, $5M funding for its percutaneous robotics navigation system

Sep. 25, 2018
By David Ho

J&J's Depuy in hot water over faulty hip implants in India

Sep. 20, 2018
By David Ho

U.S.-Israel collaboration results in Vitalminer novel monitoring tech

Sep. 18, 2018
By David Ho

Indian rupee depreciation is a good news, bad news scenario for drugmakers

Sep. 12, 2018
By Alex Ho and David Ho
HONG KONG – Some outward-looking Indian drugmakers may be benefiting from the cheapest rupee ever, but others, which hedged their currency bets, could take a hit.
Read More

Indian rupee depreciation is a good news, bad news scenario for drugmakers

Sep. 10, 2018
By Alex Ho and David Ho
HONG KONG – Some outward-looking Indian drugmakers may be benefiting from the cheapest rupee ever, but others, which hedged their currency bets, could take a hit.
Read More
View All Articles by David Ho

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for May 13, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for May 13, 2025.
  • Drug capsule and dollar sign

    Little bite from voluntary most-favored nation Rx pricing order

    BioWorld
    After a week of hype, the most-favored nation (MFN) drug pricing executive order (EO) U.S. President Donald Trump signed May 12 has a lot of bark but little bite,...
  • AI generated, 3D rendering of protein degradation

    AACR 2025: Induced proximity strategy, beyond degraders

    BioWorld
    Targeted protein degradation has yet to notch its first approval. But with more than two dozen agents now in clinical trials, the strategy’s ultimate clinical...
  • Disitamab vedotin

    China’s NMPA gives thumbs up to Remegen’s ADC targeting HER2

    BioWorld
    China’s National Medical Products Administration has approved Remegen Co. Ltd.’s antibody-drug conjugate (ADC), disitamab vedotin (RC-48), for treatment of...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe